Doctors seeing rise in co-infections in kids this winter season
The good news is this isn't something necessarily new. In fact, kids have been likely co-infected with multiple viruses before.
The difference? The availability of testing to know exactly what is causing a child's sickness.
Pre-COVID, doctors say they were not always testing for multiple viruses all at one time. Now that they are able to, the data shows a lot of co-infections, especially right now.
'A lot of these viruses are really spread through the air, but the majority of the spread, like with RSV is through close contact, so, really being careful about strict hand washing is important,' Dr. Camille Sabella with the Cleveland Clinic said. 'And when kids are sick, keeping them home from school and from daycare helps as well.'
While being sick with two viruses may sound stressful, Sabella said most kids tend to handle it pretty well and are able to recover at home.
If you or your child haven't been vaccinated yet, there's still time. Flu season, for example, usually goes until May.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
39 minutes ago
- Business Wire
Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Crossbow Therapeutics, Inc., a biotechnology company developing T-Bolt™ therapies, a novel class of T-cell receptor (TCR)-mimetic antibody therapeutics, today announced the nomination of its second development candidate, CBX-663, for the treatment of a broad range of solid tumor and hematologic malignancies. The next-generation T-cell engager targets telomerase reverse transcriptase (TERT), a protein that drives tumor growth and is expressed in up to 95% of cancers. 1,2 CBX-663, a bispecific antibody, binds to TERT-derived peptide human leukocyte antigen (pHLA) complexes on the surface of tumor cells and activates T-cells through a CD3-binding arm. The molecule includes two binding domains for TERT, which increase its ability to engage tumor cells and boost immune activation. 'CBX-663 illustrates how Crossbow's TCR-mimetic platform can unlock new opportunities for antibody-based cancer therapies,' said Briggs Morrison, MD, Chief Executive Officer of Crossbow. 'With strong preclinical performance selectively targeting a pHLA expressed across a broad range of cancers, CBX-663 has the potential to offer a meaningful new treatment option for patients with limited therapeutic options.' In preclinical studies, CBX-663 drove potent, antigen-specific tumor killing across multiple TERT-positive cancer models, with minimal activity against TERT-negative or HLA-mismatched cells. The candidate also demonstrated a favorable safety profile and pharmacokinetics comparable to conventional antibody therapies. Crossbow presented data summarizing the initial characterization of CBX-663 at the 2025 Annual Meeting of the American Association for Cancer Research (AACR). Although TERT resides inside the cell, HLA molecules can present fragments of the protein, known as peptides, on the tumor surface. CBX-663 recognizes one of those peptides, the HLA-A*02:01-restricted TERT540 peptide, and redirects T-cells to attack tumor cells. CBX-663 demonstrated broad cytotoxic activity in vitro in both solid and hematologic cancer cell lines, as well as in primary patient samples ex vivo. In vivo studies further confirmed its anti-tumor efficacy and tolerability. 'CBX-663 reflects the depth of antibody discovery and protein engineering that underpins our T-Bolt™ platform and our ability to generate highly selective, potent molecules against difficult cancer targets,' said Dmitri Wiederschain, PhD, Chief Scientific Officer of Crossbow. 'Its performance in preclinical models reinforces the promise of TCR-mimetic therapeutics, and we're excited to continue advancing this program.' Crossbow discovered and developed CBX-663 through its proprietary T-Bolt™ platform, which uses optimized antibody libraries and precision screening to find high-affinity, specific binders to intracellular tumor antigens displayed as pHLA complexes. The nomination of CBX-663 underscores the platform's potential to deliver a scalable pipeline of T-cell engagers for difficult-to-treat cancers. About Crossbow Therapeutics, Inc. Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company's T-Bolt™ therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow's efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer. For more information about Crossbow Therapeutics, visit
Yahoo
42 minutes ago
- Yahoo
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ('Sight Sciences' or the 'Company'), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the second quarter ended June 30, 2025, after the market close on Thursday, August 7, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event. About Sight Sciences Sight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System and OMNI® Edge Surgical System are implant-free, minimally invasive glaucoma surgery technologies (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The OMNI Surgical System is CE Marked for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world's leading cause of irreversible blindness. The SION® Surgical System is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company's TearCare® System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit for more information. Sight Sciences, the Sight Sciences logo, TearCare, and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories. © 2025 Sight Sciences. All rights reserved. Media contact:pr@ Investor contact:Philip TaylorGilmartin in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Hims & Hers (HIMS) Soars 16% on Bullish Analyst Outlook
We recently published . Hims & Hers Health, Inc. (NYSE:HIMS) is one of the biggest performers on Wednesday. Hims & Hers rallied for a second day on Wednesday, adding 16.02 percent to close at $58.02 apiece as investors took path from an investment firm's bullish outlook and rating for the company. In a market note on Wednesday, Zacks Research gave Hims & Hers Health, Inc. (NYSE:HIMS) a 'strong buy' recommendation on expectations that its 2025 earnings per share will improve by 177.8 percent year-on-year. Zacks also underscored Hims & Hers Health, Inc.'s (NYSE:HIMS) expansion program with the recent acquisition of ZAVA, a European digital health platform operating in the UK, Germany, France, and Ireland. 'This acquisition, announced in June 2025, grants Hims & Hers access to over 1.3 million active customers and nearly 2.3 million consultations delivered in 2024 by ZAVA's in-house medical team,' Zacks noted. 'The integration of ZAVA's technology with Hims & Hers' established brand positions it to deliver personalized, seamless digital healthcare across key European markets,' it added. Pixabay/Public Domain According to Hims & Hers Health, Inc. (NYSE:HIMS), it is scheduled to announce the results of its April-June earnings performance after market close on August 4. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
